Pantoprazole
[CAS# 102625-70-7]

Identification

• Classification: API >> Digestive system medication >> Acid and gastric mucosal protective drugs
• Name: Pantoprazole
• Synonyms: 6-(Difluoromethoxy)-2-[(3,4-dimethoxypyridin-2-yl)methylsulfinyl]-1H-benzimidazole
• Molecular Formula: C₁₆H₁₅F₂N₃O₄S
• Molecular Weight: 383.37
• CAS Registry Number: 102625-70-7 (154644-14-1)
• EC Number: 600-331-6
• SMILES: COC1=C(C(=NC=C1)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC(F)F)OC

Properties

• Solubility: 10 mM (DMSO) (Expl.)
• Density: 1.5±0.1 g/cm³, Calc.^*
• Index of Refraction: 1.643, Calc.^*
• Boiling Point: 586.9±60.0 ºC (760 mmHg), Calc.^*
• Flash Point: 308.7±32.9 ºC, Calc.^*

^* Calculated using Advanced Chemistry Development (ACD/Labs) Software.

Safety Data

• Hazard Symbols: GHS07;GHS08;GHS09 Warning
• Hazard Statements: H302+H312+H332-H302-H312-H315-H319-H335-H336-H341H351-H4990H410-H412
• Precautionary Statements: P203-P261-P264-P264+P265-P270-P271-P273-P280-P301+P317-P302+P352-P304+P340-P305+P351+P338-P317-P318-P319-P321-P330-P332+P317-P337+P317-P362+P364-P391-P403+P233-P405-P501

Hazard Classification

Hazard	Class	Category Code	Hazard Statement
Acute toxicity	Acute Tox.	4	H302
Skin irritation	Skin Irrit.	2	H315
Specific target organ toxicity - single exposure	STOT SE	3	H335
Eye irritation	Eye Irrit.	2	H319
Acute toxicity	Acute Tox.	4	H332
Acute toxicity	Acute Tox.	4	H312
Acute hazardous to the aquatic environment	Aquatic Acute	1	H400
Chronic hazardous to the aquatic environment	Aquatic Chronic	3	H412
Chronic hazardous to the aquatic environment	Aquatic Chronic	1	H410
Specific target organ toxicity - single exposure	STOT SE	3	H336

Discovory and Applicatios

Pantoprazole is a proton pump inhibitor (PPI) that was first synthesized in the late 1980s by researchers at Byk Gulden, a German pharmaceutical company. It was developed to inhibit gastric acid secretion by selectively targeting the H+/K+ ATPase enzyme system in the stomach. The discovery of pantoprazole marked a significant advancement in the treatment of acid-related disorders, providing an effective therapeutic option with improved stability and bioavailability compared to earlier PPIs.

The synthesis of pantoprazole involves the modification of the benzimidazole core structure, which enhances its acid stability and selective inhibition of gastric proton pumps. As a prodrug, pantoprazole is activated in the acidic environment of the stomach, where it covalently binds to cysteine residues on the proton pump, leading to prolonged suppression of acid secretion. This mechanism contributes to its efficacy in treating gastroesophageal reflux disease (GERD), peptic ulcers, and Zollinger-Ellison syndrome.

Pantoprazole has gained widespread clinical use due to its favorable pharmacokinetics and lower potential for drug interactions compared to other PPIs. It is commonly prescribed for short-term and long-term management of acid-related disorders. Studies have shown that pantoprazole maintains gastric pH levels more consistently, which is beneficial for patients requiring long-term acid suppression therapy. Additionally, pantoprazole has been evaluated for its potential protective effects against nonsteroidal anti-inflammatory drug (NSAID)-induced gastric mucosal damage.

Despite its therapeutic benefits, pantoprazole has been associated with concerns regarding long-term use, including potential risks of nutrient malabsorption, altered gut microbiota, and increased susceptibility to infections. Ongoing research aims to further elucidate the long-term safety profile of pantoprazole and optimize its clinical applications.